AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25542917 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhalers
Number of subjects: 120
Study 25542917 — intervention group
Group type: COMPARATOR
Intervention: NRT strength of sensation scores
Number of subjects: 120
Study 25542917 — intervention group
Group type: COMPARATOR
Intervention: Taste receptor genotype
Number of subjects: 120
Study 23576518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) group intervention, 8 weeks duration
Number of subjects: 60
Study 23576518 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study 22436438 — intervention group
Group type: EXPERIMENTAL
Intervention: Beginning readers (six and eight years old) in the Identity condition
Number of subjects: 3
Study 22436438 — intervention group
Group type: EXPERIMENTAL
Intervention: Beginning readers (six and eight years old) in the Variation condition
Number of subjects: 3
Study 22436438 — intervention group
Group type: COMPARATOR
Intervention: Preliterate children
Number of subjects: 3
Study 19482902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 70
Study 19482902 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound Therapy (US)
Number of subjects: 70
Study 16945487 — intervention group
Group type: EXPERIMENTAL
Intervention: brief coping skills intervention
Number of subjects: 98
Study 16945487 — intervention group
Group type: EXPERIMENTAL
Intervention: brief motivational enhancement intervention
Number of subjects: 98
Study 16945487 — intervention group
Group type: COMPARATOR
Intervention: waiting list condition
Number of subjects: 98
Study 14709949 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 15 mg/d
Number of subjects: 164
Study 14709949 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine 300 mg/d
Number of subjects: 164
Study 14709949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/d
Number of subjects: 164
Study 14709949 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 750 mg/d
Number of subjects: 164
Study 14709949 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 20 mg/d
Number of subjects: 164
Study 14709949 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 6-8 mg/d increased to 16 mg/d
Number of subjects: 164
Study 14709949 — intervention group
Group type: COMPARATOR
Intervention: Metabolic inhibition (concomitant administration of CYP450 inhibitors)
Number of subjects: 164
Study 11333687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group asthma education program
Number of subjects: 73
Study 11333687 — intervention group
Group type: COMPARATOR
Intervention: Individual and simplified education with a self‐management plan
Number of subjects: 73
Study 9142503 — intervention group
Group type: EXPERIMENTAL
Intervention: Red spectral light
Number of subjects: 92
Study 9142503 — intervention group
Group type: EXPERIMENTAL
Intervention: Green spectral light
Number of subjects: 92
Study 9142503 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow spectral light
Number of subjects: 92
Study 9142503 — intervention group
Group type: COMPARATOR
Intervention: Blue spectral light
Number of subjects: 92
Study 9142503 — intervention group
Group type: COMPARATOR
Intervention: White light
Number of subjects: 92
Study 7812225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography measurements using Agema 870 thermovision unit
Number of subjects: 80
Study 7812225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography measurements for specific diagnoses (osteosarthrosis, internal derangement, normal)
Number of subjects: 80
Study 7812225 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature measures from thermography
Number of subjects: 80
Study 2961818 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine (40-micrograms dose)
Number of subjects: 61
Study 2961818 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant-derived vaccine (40-micrograms and 20-micrograms doses)
Number of subjects: 61
Study 30305151 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Exercise (CAE)
Number of subjects: 75
Study 30305151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise with Motor Complexity (AEMC)
Number of subjects: 75
Study 30305151 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control (C)
Number of subjects: 75
Study 30305151 — intervention group
Group type: EXPERIMENTAL
Intervention: CAE and AEMC
Number of subjects: 75
Study 28058748 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (12 sessions)
Number of subjects: 100
Study 28058748 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 100
Study 26258145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg (group C)
Number of subjects: 51
Study 26258145 — intervention group
Group type: COMPARATOR
Intervention: Ramosetron 0.3 mg (group A)
Number of subjects: 51
Study 23107669 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit-4-Fun Program (8-week intervention)
Number of subjects: 213
Study 21415358 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEL dietary intervention
Number of subjects: 447
Study 21415358 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm
Number of subjects: 447
Study 21415358 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bioavailable testosterone
Number of subjects: 447
Study 21415358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline total testosterone
Number of subjects: 447
Study 21415358 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline bioavailable testosterone
Number of subjects: 447
Study 21415358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline total testosterone
Number of subjects: 447
Study 21415358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower baseline bioavailable testosterone
Number of subjects: 447
Study 17657228 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin-enriched formula (EF)
Number of subjects: 216
Study 17657228 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 216
Study 17657228 — intervention group
Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 216
Study 16792285 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation targeted to dyscoordination, weakness, and dysfunctional task component execution
Number of subjects: 0
Study 14528615 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus monitoring
Number of subjects: 0
Study 14528615 — intervention group
Group type: COMPARATOR
Intervention: Monitoring-only
Number of subjects: 0
Study 11033978 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weight maintenance over three years
Number of subjects: 854
Study 11033978 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weight loss and maintenance
Number of subjects: 854
Study 11033978 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain within the first twelve months
Number of subjects: 854
Study 9387643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide pulse therapy every 2 weeks (15 mg/kg per pulse)
Number of subjects: 52
Study 9387643 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulse therapy every 4 weeks (15 mg/kg per pulse)
Number of subjects: 52
Study 9387643 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 52
Study 1575253 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental psychiatric consultation
Number of subjects: 741
Study 1575253 — intervention group
Group type: COMPARATOR
Intervention: Baseline control
Number of subjects: 741
Study 1575253 — intervention group
Group type: COMPARATOR
Intervention: Contemporaneous control
Number of subjects: 741
Study 6374280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg oral dose
Number of subjects: 10
Study 6374280 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg oral dose with standard breakfast
Number of subjects: 10
Study 6374280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31794575 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-glorifying commercial
Number of subjects: 0
Study 31794575 — intervention group
Group type: COMPARATOR
Intervention: Neutral commercial
Number of subjects: 0
Study 31794575 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal condition
Number of subjects: 0
Study 31794575 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-arousal condition
Number of subjects: 0
Study 31794575 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessibility to risk-positive cognitions
Number of subjects: 0
Study 29452178 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 200
Study 29452178 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 200
Study 27379776 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser 904 nm
Number of subjects: 54
Study 27379776 — intervention group
Group type: EXPERIMENTAL
Intervention: LED 945 nm
Number of subjects: 54
Study 27379776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 25390695 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (25 hours infusion)
Number of subjects: 61
Study 25390695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 25390695 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan and Placebo (comparison)
Number of subjects: 61
Study 23075178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 1 mg/kg
Number of subjects: 526
Study 23075178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 3 mg/kg
Number of subjects: 526
Study 23075178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/kg
Number of subjects: 526
Study 23075178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study 23075178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (maintenance) 90 mg
Number of subjects: 526
Study 23075178 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 526
Study 20156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day), oral supplementation with eicosapentaenoic acid, L-carnitine (4 g/day), thalidomide (200 mg/day)
Number of subjects: 332
Study 20156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (200 mg/day)
Number of subjects: 332
Study 20156909 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (4 g/day)
Number of subjects: 332
Study 20156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation with eicosapentaenoic acid
Number of subjects: 332
Study 20156909 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone (500 mg/day) or Megestrol acetate (320 mg/day)
Number of subjects: 332
Study 17360171 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Number of subjects: 100
Study 17360171 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 400 mg QID + 200 microg beclomethasone dipropionate (BDP) BID
Number of subjects: 100
Study 17360171 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone 400 microg BID
Number of subjects: 100
Study 17360171 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 100
Study 16352931 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (GOS) 3.6 mg/4 weeks for 2 years
Number of subjects: 207
Study 16352931 — intervention group
Group type: COMPARATOR
Intervention: Goserelin (GOS)
Number of subjects: 207
Study 16352931 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day
Number of subjects: 207
Study 12140499 — intervention group
Group type: EXPERIMENTAL
Intervention: Family presence during invasive procedures and resuscitations
Number of subjects: 20
Study 9595984 — intervention group
Group type: EXPERIMENTAL
Intervention: EPDF
Number of subjects: 53
Study 9595984 — intervention group
Group type: EXPERIMENTAL
Intervention: ARJP/EPDF
Number of subjects: 53
Study 7666098 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CHOP (full doses every 3 weeks)
Number of subjects: 38
Study 7666098 — intervention group
Group type: COMPARATOR
Intervention: Weekly CHOP (one-third doses weekly)
Number of subjects: 38
Study 7666098 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CHOP
Number of subjects: 38
Study 7666098 — intervention group
Group type: COMPARATOR
Intervention: Weekly CHOP
Number of subjects: 38
Study 2540245 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ACV (daily suppressive oral acyclovir)
Number of subjects: 0
Study 2540245 — intervention group
Group type: COMPARATOR
Intervention: PLC/ACV (placebo and acyclovir for 5 days)
Number of subjects: 0
Study 2540245 — intervention group
Group type: COMPARATOR
Intervention: Control group (infrequently recurring genital HSV-2)
Number of subjects: 0
Study 2540245 — intervention group
Group type: EXPERIMENTAL
Intervention: Both S-ACV and PLC/ACV
Number of subjects: 0
Study 2540245 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpopulation given a second year of S-ACV
Number of subjects: 0
Study 31622044 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powders (MNP) delivered by community volunteers alongside early childhood development interventions and seasonal malaria chemoprevention.
Number of subjects: 0
Study 28364165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.4% (n = 30)
Number of subjects: 54
Study 28364165 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (n = 30)
Number of subjects: 54
Study 26429115 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched multiple-behavior intervention (n=332)
Number of subjects: 384
Study 26429115 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (n=52)
Number of subjects: 384
Study 23234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral random generation (secondary task loading executive functions)
Number of subjects: 0
Study 23234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory spatial localization task (secondary task loading spatial working memory)
Number of subjects: 0
Study 23234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Articulatory suppression (secondary task loading phonological loop)
Number of subjects: 0
Study 23234420 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor planning group
Number of subjects: 0
Study 21641186 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe-fed CLP babies
Number of subjects: 57
Study 21641186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-and-spoon-fed CLP babies
Number of subjects: 57
Study 21641186 — intervention group
Group type: COMPARATOR
Intervention: Normal breast-fed babies
Number of subjects: 57
Study 21641186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-and-spoon-fed CLP babies (artificial and breast milk)
Number of subjects: 57
Study 21641186 — intervention group
Group type: COMPARATOR
Intervention: Normal babies
Number of subjects: 57
Study 21641186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cup-and-spoon-fed babies
Number of subjects: 57
Study 19602903 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease patients (CKD)
Number of subjects: 155
Study 19602903 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 155
Study 16525576 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral aspirin for 5 days
Number of subjects: 0
Study 16525576 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg oral aspirin for 5 days
Number of subjects: 0
Study 16525576 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro aspirin (150 micromol/l)
Number of subjects: 0
Study 16525576 — intervention group
Group type: COMPARATOR
Intervention: NS398 (COX-2 inhibitor)
Number of subjects: 0
Study 16525576 — intervention group
Group type: COMPARATOR
Intervention: SB203580 (p38-MAPK inhibitor)
Number of subjects: 0
Study 12612386 — intervention group
Group type: EXPERIMENTAL
Intervention: LP stent
Number of subjects: 1003
Study 12612386 — intervention group
Group type: COMPARATOR
Intervention: Guidant stent
Number of subjects: 1003
Study 11115036 — intervention group
Group type: COMPARATOR
Intervention: 150 mL/kg per day
Number of subjects: 54
Study 11115036 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL/kg per day
Number of subjects: 54
Study 9118717 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual chest radiographs (CXRs) with sputum cytologic findings in the experimental group
Number of subjects: 0
Study 9118717 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular and frequent rescreening CXRs in the experimental group
Number of subjects: 0
Study 9118717 — intervention group
Group type: COMPARATOR
Intervention: Sporadic and/or infrequent rescreening in the control group
Number of subjects: 0
Study 1332974 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polyglycolic acid rods
Number of subjects: 30
Study 1332974 — intervention group
Group type: COMPARATOR
Intervention: Kirschner wires
Number of subjects: 30
Study 3490803 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.2 mg kg‐1 body weight, reduced to 1.8 mg kg‐1 with opioids and benzodiazepins)
Number of subjects: 100
Study 3490803 — intervention group
Group type: COMPARATOR
Intervention: Etomidate
Number of subjects: 100
Study 29248753 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (300000 Unit, single intramuscular injection)
Number of subjects: 46
Study 29248753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26689781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 300 µg and intravenous patient-controlled analgesia (IV-PCA)
Number of subjects: 45
Study 26689781 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (IV-PCA) alone
Number of subjects: 45
Study 24936901 — intervention group
Group type: EXPERIMENTAL
Intervention: Braking force of 11% of body mass (BM)
Number of subjects: 16
Study 24936901 — intervention group
Group type: COMPARATOR
Intervention: Braking force of 8.7% of body mass (BM)
Number of subjects: 16
Study 22680789 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 258
Study 22680789 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 258
Study 22680789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 258
Study 22680789 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 258
Study 22680789 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall opioids
Number of subjects: 258
Study 19889470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg/day)
Number of subjects: 32
Study 19889470 — intervention group
Group type: COMPARATOR
Intervention: Domperidone (30 mg/day)
Number of subjects: 32
Study 18794551 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg orally once daily
Number of subjects: 371
Study 18794551 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg orally once daily
Number of subjects: 371
Study 15983794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine depletion (TPD)
Number of subjects: 18
Study 15983794 — intervention group
Group type: EXPERIMENTAL
Intervention: D1/D2 receptor stimulation under TPD conditions (using pergolide)
Number of subjects: 18
Study 15983794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12017399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 0
Study 12017399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10406826 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (3.0 pmol. kg(‐1). min(‐1))
Number of subjects: 8
Study 10406826 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM (2.7 pmol. kg(‐1). min(‐1))
Number of subjects: 8
Study 10406826 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM (5.4 pmol. kg(‐1). min(‐1))
Number of subjects: 8
Study 10406826 — intervention group
Group type: EXPERIMENTAL
Intervention: ADM and BNP combined
Number of subjects: 8
Study 10406826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7726426 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 8 micrograms/kg (Group C)
Number of subjects: 45
Study 7726426 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 micrograms/kg + morphine 2 mg (Group CM)
Number of subjects: 45
Study 7726426 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine 50 micrograms/kg (Group M)
Number of subjects: 45
Study 2285385 — intervention group
Group type: EXPERIMENTAL
Intervention: Himega (2 g/day or 4 g/day of n‐3 fatty acid)
Number of subjects: 22
Study 2285385 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride-based fish oil (2 g/day or 4 g/day of n‐3 fatty acid)
Number of subjects: 22
Study 2285385 — intervention group
Group type: EXPERIMENTAL
Intervention: Himega (2 g/day of n‐3 fatty acid)
Number of subjects: 22
Study 2285385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 22
Study 7231917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine hydrochloride (1% base)
Number of subjects: 32
Study 7231917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 29265941 — intervention group
Group type: EXPERIMENTAL
Intervention: Job club program
Number of subjects: 87
Study 29265941 — intervention group
Group type: COMPARATOR
Intervention: Supported employment
Number of subjects: 87
Study 31188145 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone injection
Number of subjects: 30
Study 31188145 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 30
Study 27864015 — intervention group
Group type: EXPERIMENTAL
Intervention: ePCR model (ensemble of penalised Cox regression models)
Number of subjects: 2346
Study 27864015 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference model (based on eight clinical variables and a penalised Cox proportional-hazards model)
Number of subjects: 2346
Study 27864015 — intervention group
Group type: EXPERIMENTAL
Intervention: ENTHUSE M1 cohort validation
Number of subjects: 2346
Study 27864015 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis across all methods
Number of subjects: 2346